Questcor Pharmaceuticals — Q3 2011 Earnings Presentation
15 slides from Questcor Pharmaceuticals's earnings presentation, Oct 27, 2011
Slide 1: Third Quarter 2011 Conference Call
1 NASDAQ: QCOR Third Quarter 2011 Conference Call Exhibit 99.3 NASDAQ: QCOR Third Quarter 2011 Conference Call
Slide 2: Conference Call Logistics
2 • • Telephone replay is available by dialing: – U.S.: 800-406-7325 – International: 303-590-3030 – Replay Passcode: 4480054 Conference Call Logistics • • Telephone replay is available by dialing: – U.S.: 800-406-7325 – International: 303-590-3030 – Replay Passcode: 4480054 Today’s webcast, accompa
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance. Note: Except for the historical information contained herein, this press release contains forward-looking statements t
Slide 4: Strong Third Quarter Results
4 • 886 paid MS scripts – Up 174% YOY – Up 18% sequentially • 60 paid NS scripts – Much better than expected – Sales force expansion complete • Record financial performance – 2,910 vials – $59.8M in net sales – $0.35 EPS Strong Third Quarter Results • 886 paid MS scripts – Up 174% YOY – Up 18% seque
Slide 5: MS Sales - Record of Consistent Growth
5 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i
Slide 6: Monthly MS Sales Have 160% CAGR
6 Monthly MS Sales Have 160% CAGR 15-30 reps 30-38 reps 38-77 reps
Slide 7: NS Sales – Off to a Good Start
7 NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo
Slide 8: MS Sales - Record of Consistent Growth
8 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i
Slide 9: NS Sales – Off to a Good Start
9 NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo
Slide 10: Total Acthar Sales Force
10 • Specialty Sales Force – Main focus on MS (~80%), 15% on NS, 5% on IS – 77 representatives, 13 regional managers, one national director • Nephrology Sales Force – Focus 100% on nephrotic syndrome – 28 representatives, 4 regional managers, one national director • Combined Forces are calling on –
Slide 11: ASN Annual Meeting 2011: Acthar-Related Abstracts
11 • Treatment of Resistant Glomerular Diseases with ACTH Gel: A Prospective Trial [G. Appel, et al ] • Response of Anti-PLA2R to Adrenocorticotropic hormone (ACTH) Gel in Primary Membranous Nephropathy [L. Beck, et al ] • Adrenocortocortropin (ACTH) gel suppresses renal tubulointerstitial inflammat
Slide 12: Q3-2011 Financial Results
12 Record Net Sales (up 91%) and Solid Earnings (EPS up 94%) Q3-2011 Q3-2010 12 Q3-2011 Financial Results Record Net Sales (up 91%) and Solid Earnings (EPS up 94%) • Third quarter vials shipped: 2,910 • Third quarter cash flow from operations: $32.6M • Channel inventory estimated to be within histor
Slide 13: Debt-free balance sheet; Questcor is Cash Flow Positive
13 10/21/11 Debt-free balance sheet Questcor is Cash Flow Positive *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments Accounts Receivable $180M* $24M Debt-free balance sheet
Slide 14: Investment Highlights
14 Investment Highlights Acthar has sustainable competitive advantages-without FDA approval risk Acthar is approved for 19 indications-many in large markets with sizable unmet need Sales in MS and NS are growing rapidly, yet market penetration is low High margins provide good operating leverage Prof
Slide 15: Third Quarter 2011 Conference Call
15 NASDAQ: QCOR Third Quarter 2011 Conference Call NASDAQ: QCOR Third Quarter 2011 Conference Call
Questcor Pharmaceuticals — Q3 2011 Earnings Presentation on 6ix